Thalys Medical Technology Group Corporation (SHSE: 603716)
Health Care · Biotechnology · CN
CN¥16.47
-0.90% today · -33.8% 1Y
Thalys Medical Technology Group Corporation (SHSE: 603716) operates in the Biotechnology industry within the Health Care sector. The company is valued at $545.42M and employs 1,045 people.
Over the last twelve months the share price has lost 33.8%, trading between 12.92 and 31.86.
Tweenvest scores Thalys Medical Technology Group Corporation across four factors: quality 47/100, value 43/100, growth 0/100. Its strongest factor is quality.
603716 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $545.42M
- Revenue (TTM)
- $123.11M
- P/E
- —
- EPS
- -0.94
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- CN¥31.86
- 52-week low
- CN¥12.92
- Avg volume (3M)
- —
- Shares outstanding
- 221.81M
- Employees
- 1,045
- Next earnings
- —
About Thalys Medical Technology Group Corporation
Thalys Medical Technology Group Inc. is a Chinese enterprise that specializes in providing intensive medical business and operational services. The company, established in 2004, is headquartered in Wuhan, China. It previously operated under the name Thalys Medical Technology Inc. before officially adopting its current designation in September 2020.
- ISIN
- CNE1000030C3
- Founded
- 2004
- Listed since
- Oct 31, 2016
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zhejiang Orient Gene Biotech Co., LtdSHSE: 688298 | $557.20M | CN¥19.50 | +0.67% |
| DBV Technologies S.A.ENXTPA: DBV | $555.98M | €1.68 | -11.87% |
| Jacobio Pharmaceuticals Group Co., Ltd.SEHK: 1167 | $555.24M | HK$5.57 | -7.40% |
| Jiangsu Sihuan Bioengineering Co., LtdSZSE: 000518 | $553.35M | CN¥3.60 | +0.28% |
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $541.29M | HK$10.43 | -2.71% |
| Valneva SEENXTPA: VLA | $537.87M | €2.53 | +0.08% |
| Bright Minds Biosciences Inc.CNSX: DRUG | $533.01M | CA$77.10 | +9.22% |
| Puma Biotechnology, Inc.NasdaqGS: PBYI | $531.17M | $10.29 | 0.00% |
Figures last refreshed Oct 11, 2026.